FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
- Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
- This breakthrough follows years of NASH patient-led, multi-stakeholder advocacy and partnership with researchers in both drug and diagnostic development.
- “Today’s announcement represents the culmination of the work of the united NASH community.
- It is particularly satisfying that we can mark Women’s History Month with a breakthrough from a female-founded company.